The Phase II clinical trial of Kaifeng Pharmaceutical's "Fruitan" for the treatment of androgenetic alopecia was approved by the FDA

On July 11, Kaifeng Pharmaceutical announced that the Phase II clinical trial application of Freitan (KX-826) for the treatment of androgenetic alopecia has been approved by the US FDA
.

Androgenic alopecia (androgenic alopecia, AGA) is one of the most common hair loss diseases in which hair follicles are miniaturized
.

The current treatment methods for androgenetic alopecia include systemic medication, topical medication, hair transplantation, mesotherapy, and low-energy laser therapy
.

The difference in the mechanism of action between Phraytaen and Finasteride (Source: Prospectus of Kaifeng Pharmaceutical)

Freetarin is a small molecule AR antagonist and one of the two core products of Pioneer Pharmaceutical
.

The Phase II clinical trial approved by the FDA is a randomized, double-blind, placebo-controlled, parallel group study, which aims to explore the effectiveness and safety of Freitan in the treatment of male subjects with androgenetic alopecia
.